

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/578,589-Conf. #9455
<i>(Use as many sheets as necessary)</i>				Filing Date	December 13, 2006
				First Named Inventor	Anne-Sophie Bessis
				Art Unit	1625
				Examiner Name	T. A. Solola
Sheet	1	of	2	Attorney Docket Number	65517(53196)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AA		US-2003/0149049	08-07-2003	Arkin et al.	
AB		US-3,991,064	11-09-1976	Brown et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
BA		WO-03/027080	04-03-2003	Mitsubishi Pharma Corporation, Sanofi-Synthelabo	
BB		WO-2004/085408	10-07-2004	Mitsubishi Pharma Corporation, Sanofi-Synthelabo	
BC		WO-2004/052864	06-24-2004	Pfizer Products Inc.	
BD		WO-01/02375	01-11-2001	AXYS Pharmaceuticals, Inc.	
BE		WO-01/54507	08-02-2001	Akkadix Corporation	
BF		WO-03/037888	05-08-2003	Mitsubishi Pharma Corporation, Sanofi-Synthelabo	
BG		WO-91/04250	04-04-1991	Schering Aktiengesellschaft Berlin Und Bergkamen	
BH		GB-950,872	02-26-1964	Boissier, et al.	
BI		WO-03/066595	08-14-2003	Euro-ceiltique S.A.	
BJ		WO-2004/011441	02-05-2004	Euro-ceiltique S.A.	
BK		WO-2004/014902	02-19-2004	Astrazeneca AB	
BL		WO-2004/029031	04-08-2004	Euro-ceiltique, S.A.	
BM		WO-2004/038374	05-06-2004	Merck & Co., Inc.	
BN		WO-2004/058754	07-15-2004	Euro-ceiltique S.A.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/578,589-Conf. #9455
<i>(Use as many sheets as necessary)</i>				Filing Date	December 13, 2006
				First Named Inventor	Anne-Sophie Besis
				Art Unit	1625
				Examiner Name	T. A. Solola
Sheet	2	of	2	Attorney Docket Number	65517(53196)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	²
	CA	Rogers, et al., Neurobiology of Aging, Vol. 17, No. 5, pp. 681-686 (1996).	
	CB	Yan, et al., J. Comb. Chem., Vol. 5, No. 5, pp. 547-559 (2003).	
	CC	Phillips, et al., J. Med. Chem., Vol. 35, No. 4, pp. 743-750 (1992).	
	CD	Toja, E. et al., Farmaco Sci., Vol. 39, No. 5, pp. 450-462 (1984).	
	CE	CAS Registry No. 695195-63-2, Chemical Library, Supplier: Chemical Block Ltd, CAS Registry (2004)	
	CF	Copy of Opposition filed in the name of Sanofi-Aventis in corresponding European Patent No. 1 685 105 B1.	
	CG	Copy of Opposition filed in the name of Dr. Thorsten Bausch in corresponding European Patent No. 1 685 105 B1.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

BOS2 771136.1